Merck

Codexis extends collaboration with Merck to 2015

Wednesday, May 23, 2012 09:50 AM

Redwood City, Calif.-based Codexis, a developer of cost-advantaged processes for the production of biofuels, bio-based chemicals and pharmaceuticals, has extended its catalyst and process development collaboration with Merck to develop enzymes for use in pharmaceutical manufacturing for three more years.

More... »


Merck announces Swiss efficiency program, closure of Geneva office

Wednesday, April 25, 2012 10:05 AM

Global pharmaceutical and chemical company Merck Serono has announced efficiency plans for its Swiss operations as part of its comprehensive transformation program—focused on addressing unprecedented market shifts, increasing competition in key product areas and existing inefficiencies in its own organization.

More... »


Report: Pharmaceutical market grew by 5.3% in 2011

Friday, April 20, 2012 12:29 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, found that in 2011, the global pharmaceutical market, in dollar terms, benefitted significantly from positive currency effects.

More... »

Merck, Endocyte to develop and commercialize cancer drug vintafolide

Monday, April 16, 2012 10:55 AM

Merck has entered into an agreement with Endocyte, a biopharmaceutical company based in West Lafayette, Ind., to develop and commercialize Endocyte's novel investigational therapeutic candidate vintafolide (EC145), which gained orphan drug status from the E.U. in March.

More... »

Flagship and Merck to foster early-stage life sciences innovation

Wednesday, April 11, 2012 12:37 PM

Flagship Ventures, a venture capital firm focused on healthcare and sustainability, has partnered with Merck Research Laboratories (MRL) and its newly formed Merck Research Ventures Fund to back new ventures that apply scientific breakthroughs to the development of new drugs in areas of unmet medical need.

More... »

Threshold earns $20 million milestone payment from Merck

Wednesday, April 11, 2012 11:50 AM

Threshold Pharmaceuticals, a biotech based in South San Francisco, has earned a $20 million milestone payment from Merck for achieving a statistically significant progression free survival benefit in its 214-patient randomized controlled phase II clinical trial (404 trial).

More... »

Burrill wraps up life sciences industry for Q1 2012

Wednesday, April 4, 2012 03:00 PM

Burrill & Company, a diversified global financial services firm focused on the life sciences industry, has identified more than $2.6 billion in expected funding through nine translational research and early-stage initiatives announced since the end of February.

More... »

Alzheimer’s plasma biomarker study yields potential for diagnostic blood tests

Friday, March 30, 2012 09:10 AM

Proteome Sciences, in collaboration with the National Institute for Health Research (NIHR) Biomedical Research Centre for Mental Health and Merck Millipore, has completed its 1,000-sample Alzheimer’s disease (AD) biomarker validation study.

More... »

Merck’s efficiency program to make cuts across all businesses and regions

Monday, February 27, 2012 03:15 PM

Merck's executive board has presented initial plans for an efficiency program spanning all businesses as part of the company's comprehensive transformation program announced last year.

More... »

Threshold, Merck to collaborate

Monday, February 6, 2012 01:51 PM

Threshold Pharmaceuticals has signed a global agreement with Germany-based Merck to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.

More... »


CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks worldwide toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs